MedTrace Logo

LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis

NCT06427720 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2024-05-24

No results posted yet for this study

Summary

Breast cancer is a leading cause of death among women globally, with significant incidence in Egypt. It is characterized by aggressive behavior and resistance to treatment, necessitating early detection methods. Research has revealed that many cancer-related mutations are in non-coding DNA, including microRNAs (miRNAs) and long non-coding RNAs (LncRNAs). miRNAs like miR-185-3p and miR-301a, and LncRNAs such as LINC00511, are potential biomarkers for cancer diagnosis due to their roles in gene regulation and stability in circulation. This study aims to explore the diagnostic utility of these biomarkers in breast cancer.

Conditions

  • Early Diagnosed Breast Cancer

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
28 Years
Max Age
82 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-21
Primary Completion
2021-05-25
Completion
2021-07-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06427720 on ClinicalTrials.gov